<DOC>
	<DOCNO>NCT01101022</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy SPD489 compare placebo executive function ( self-regulation ) behavior adults ADHD report clinically significant impairment executive function behavior everyday environment , measure self-report Behavior Rating Inventory Executive Function - Adult Version ( BRIEF-A ) Global Executive Composite ( GEC ) T-score .</brief_summary>
	<brief_title>Safety Efficacy SPD489 Executive Function Behaviors Adults With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>1 . Subject must 1855 year age , inclusive time consent . 2 . Subject establish close relationship least 6months duration screening ( Visit 1 ) informant able observe willing report subject 's behavior symptom multiple social setting course study . Informant define person domicile relationship subject . When applicable , informant subject 's spouse/significant . Additionally , informant participate subject study serve informant single subject . 3 . Subject lifestyle opinion Investigator enable subject complete study test requirement define protocol . 4 . Female subject must negative serum beta human chorionic gonadotropin ( HCG ) pregnancy test screening ( Visit 1 ) negative urine pregnancy test baseline ( Visit 0 ) agree comply applicable contraceptive requirement protocol . 5 . Subject meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ( DSMIVTR ) criteria primary diagnosis ADHD ( diagnostic code 314.00 314.01 ) establish comprehensive psychiatric evaluation review DSMIVTR criterion least 6 9 subtype criterion meet . The Adult ADHD Clinical Diagnostic Scale version 1.2 ( ACDS v1.2 ) utilize diagnostic tool . 6 . Subject total score ≥65 BRIEFA GEC Tscore selfreport baseline ( Visit 0 ) . 7 . Subject total score ≥28 use Adult ADHDRS prompt baseline ( Visit 0 ) . 8 . Subject must minimum level intellectual functioning determine Investigator screen ( Visit 1 ) . 9 . Subject able swallow capsule . 10 . Subject willing able comply test requirement define protocol . 11 . Subject informant must able provide write , personally sign date informed consent participate study accordance International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) Guidelines applicable regulation complete study related procedure . Exclusion Criteria 1 . Subject current comorbid psychiatric disorder either control medication prohibit study uncontrolled associate significant symptom . Prohibited disorder include associated diagnosis include limited severe comorbid Axis II disorder severe Axis I disorder ( Post Traumatic Stress Disorder [ PTSD ] , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , severe depressive severe anxiety disorder ) . Other symptomatic manifestation ( agitated state ) contraindicate treatment SPD489 confound efficacy safety assessment opinion examine physician also prohibit . Comorbid psychiatric diagnosis establish psychiatric evaluation include Structured Clinical Interview DSMIVTR disorder ( SCIDI ) . 2 . Subjects currently consider suicide risk , subject previously make suicide attempt currently demonstrate active suicidal ideation . 3 . The subject body mass index ( BMI ) &lt; 18.5 ≥40 . 4 . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment administer study might increase risk subject . Similarly , subject exclude additional condition ( ) Investigator 's opinion would prohibit subject completing study would best interest subject . This would include significant illness unstable medical condition could lead difficulty comply protocol . Mild , stable asthma exclusionary . 5 . Subject history seizure ( infantile febrile seizure ) , tic disorder , current diagnosis and/or know family history Tourette 's Disorder . 6 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , transient ischemic attack stroke serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant drug . 7 . Subject know family history sudden cardiac death ventricular arrhythmia . 8 . Subject clinically significant ECG clinically significant laboratory abnormality screening ( Visit 1 ) . 9 . Subject current abnormal thyroid function , define abnormal screening thyroid stimulate hormone ( TSH ) thyroxine ( T4 ) . Treatment stable dose thyroid medication least 3 month permit . 10 . Subject history moderate severe hypertension rest sit systolic blood pressure &gt; 139mmHg diastolic blood pressure &gt; 89mmHg . Subjects wellcontrolled mild moderate hypertension single antihypertensive agent allow . Combination antihypertensive medication allow . 11 . Subject take medication exclude . 12 . Subject document allergy , hypersensitivity , intolerance amphetamine . 13 . Subject document allergy , hypersensitivity , intolerance excipients investigational medicinal product . 14 . Subject fail respond one adequate course ( dose duration ) amphetamine therapy . 15 . Subject recent history ( within past 6 month ) suspect substance abuse dependence disorder ( exclude nicotine ) accordance DSMIVTR criterion . 16 . Subject positive urine drug result screening ( Visit 1 ) ( exception subject 's current stimulant therapy , ) . 17 . Subject take investigational drug take part clinical trial , include SPD489 clinical trial , within 30 day prior screen ( Visit 1 ) . 18 . Subject glaucoma . 19 . Subject take medication central nervous system ( CNS ) effect affect performance , sedate antihistamine decongestant sympathomimetics , monoamine oxidase inhibitor ( within 7 day investigational medicinal product administration ) . Stable use bronchodilator inhaler exclusionary . 20 . Subject female pregnant lactating . 21 . Subjects previously randomize study subsequently withdraw . 22 . Subject well control current ADHD medication acceptable tolerability .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>